Foodborne Toxin Linked to Faster Spread of Colorectal Cancer
A startling new discovery sheds light on a potential link between a common foodborne bacteria and the spread of colorectal cancer. Research published in the journal Cell Host & Microbe suggests that a toxin produced by a bacterium frequently responsible for food poisoning could accelerate the spread of colorectal tumors throughout the body.
This groundbreaking research, led by investigators at the UF Health Cancer Center and international collaborators, holds significant implications for early detection and treatment of this devastating disease.
The Bacteria-Cancer Connection
Colorectal cancer is the second leading cause of cancer-related deaths in the United States. While early detection significantly improves survival rates, the spread of cancer to other organs (metastasis) poses a major challenge.
This study identified a strong presence of Campylobacter jejuni, a bacterium known for causing food poisoning, in patients with colorectal metastases. Notably, patients with detectable levels of this bacteria had a significantly worse prognosis compared to those without it. These findings were confirmed in large national datasets of tumor samples, solidifying the link between Campylobacter jejuni and cancer progression.
The Role of Cytolethal Distending Toxin
The culprit behind this troubling connection appears to be a toxin produced by Campylobacter jejuni called cytolethal distending toxin (CDT). CDT was found to play a crucial role in promoting the spread of cancer cells.
Experiments using laboratory mice with metastatic lung and liver tumors, human colorectal cancer tissue, and 3D colorectal cancer tumor models, revealed how CDT accelerates cancer spread:
- CDT leads to an increased expression of enzymes linked to metastasis.
- CDT activates signaling pathways in cancer cells associated with metastasis.
- Live bacteria were recovered from tumors outside the gut, suggesting tumors create a hospitable environment for bacterial growth.
A New Avenue for Treatment and Early Detection
These findings offer exciting possibilities for new drug development and diagnostic tools. Several clinical trials are already underway investigating drugs that target the cell-signaling pathways activated by CDT.
Furthermore, understanding the presence and role of Campylobacter jejuni in tumors might lead to novel methods for early detection of metastatic colorectal cancer, allowing for prompt intervention and potentially improving patient outcomes.
Want to learn more about the latest research on colorectal cancer and treatment options? Consult with your doctor or visit the websites of reputable organizations like the National Cancer Institute and the American Cancer Society.
